Hemoglobin Levels Predict Renal Outcomes in Diabetic Kidney Disease
HCPLive
MARCH 26, 2024
A study in China identified a negative and non-linear relationship between hemoglobin levels and a renal composite end point in patients with DKD.
Diabetes Kidney Disease Outcomes 
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
The New England Journal of Medicine
MARCH 28, 2025
Among participants with type 2 diabetes and cardiovascular disease, chronic kidney disease, or both, oral semaglutide (14 mg) was associated with a lower risk of cardiovascular events than placebo after 4 years of follow-up.
Diabetes 
75
75 
Urinary Prostaglandin E2 Excretion and the Risk of Cardiovascular and Kidney Disease
Journal of the American Heart Association
FEBRUARY 16, 2024
BackgroundInhibition of prostaglandin synthesis by nonsteroidal anti‐inflammatory drugs is associated with cardiovascular mortality and kidney disease. Longitudinal associations with cardiovascular mortality and kidney outcomes (eGFR <60 or <45 mL/min per 1.73 1.54]; PGEM HR, 1.36 [95% CI, 1.10–1.67]).
Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease
Cardiovascular Diabetology
AUGUST 6, 2024
Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD). Research design and methods All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included.
FLOW: Semgalutide Provides Consistent CV Benefit Across Spectrum of Kidney Disease
HCPLive
AUGUST 31, 2024
Kenneth Mahaffey, MD, discusses FLOW trial data showing semaglutide improves cardiovascular outcomes in patients with type 2 diabetes, regardless of CKD severity.
Protein glycation products associate with progression of kidney disease and incident cardiovascular events in individuals with type 1 diabetes
Cardiovascular Diabetology
JULY 3, 2024
Despite improved glycemic treatment, the impact of glycation on pathological consequences may persist and contribute to adverse clinical outcomes in diabetes. In the present study we.
Diabetes 64
64 
Endotrophin Levels Could Predict Kidney Disease Outcomes in Type 2 Diabetes
HCPLive
JUNE 6, 2024
Alexandra Louise Møller, MS, PhD, discusses the results of a PROVALID analysis examining the predictive value of endotrophin levels for predicting CKD events.
Semaglutide Cardiovascular Outcomes Trial
American College of Cardiology
MARCH 29, 2025
The goal of the phase 3b SOUL trial was to assess the cardiovascular efficacy of oral semaglutide, a GLP-1 receptor agonist, and to determine the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or both.
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients with Diabetes
JAMA Cardiology
JANUARY 31, 2021
This meta-analysis uses data from patients with type 2 diabetes from 6 outcomes trials to investigate the association of sodium-glucose cotransporter 2 inhibitors with cardiovascular- and kidney disease–related outcomes.
Diabetes 40
40 
Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review
Circulation
MARCH 9, 2025
Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascular risk factors. Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025.
Understanding the failings of yesterday to improve the outcomes of tomorrow: a CardioRenal story
The British Journal of Cardiology
JULY 17, 2024
2–4 The studies will be well-known to nephrologists and demonstrated that angiotensin-receptor blockers (ARBs) had anti-proteinuric effects and/or slowed the decline of kidney function in patients with diabetic kidney disease. Clinicians and health care systems must be encouraged to make use of these treatments.”
Kidney Week 2023: Top Ten Takeaways
Cardiometabolic Health Congress
NOVEMBER 16, 2023
Key findings presented at the conference included disparities in access to kidney transplantation and waitlisting based on race and neighborhood characteristics, racial and ethnic differences in incident chronic kidney disease (CKD), and the use of motivational strategies to improve dialysis nonadherence among African American patients.
The Cardiometabolic Event of the Year: What to Expect at the 19th Annual Cardiometabolic Health Congress (CMHC)
Cardiometabolic Health Congress
JULY 25, 2024
Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovascular disease, and chronic kidney disease. The robust conference agenda begins with FDA updates and advancements in cardiorenal metabolic care.
Education 100
100 
Abstract 4137914: Eligibility for Semaglutide in US Adults with Diabetes and Potentially Preventable Cardiovascular Events Projected from the SUSTAIN-6 Trial
Circulation
NOVEMBER 11, 2024
Background:The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial showed cardiovascular disease (CVD) benefits of semaglutide therapy in patients with type 2 diabetes mellitus (T2DM).Purpose:To year follow-up time).Results:Among
Diabetes 40
40 
Discontinuation and reinitiation of mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction
European Journal of Heart Failure
NOVEMBER 26, 2024
Abstract Aims Mineralocorticoid receptor antagonists (MRA) improve outcomes in heart failure with reduced ejection fraction (HFrEF) but are underused. 1.34), ischaemic heart disease (HR 1.20, 95% CI 1.09–1.31), 1.29), diabetes mellitus (HR 1.15, 95% CI 1.04–1.27) m 2 (hazard ratio [HR] 1.75, 95% confidence interval [CI] 1.34–2.27),
Abstract 4113864: Hyperkalemia In Patients With Heart Failure Correlates to Worse Inpatient Outcomes
Circulation
NOVEMBER 11, 2024
This study evaluates the outcomes in patients admitted for HF with and without hyperkalemia.Methods:We used the Nationwide Readmissions Database (NRD) from 2016-2019, extracting adult patients with a primary diagnosis of HF who were admitted between January and November of each year. vs. 2.5%, p < 0.001). 2], p<0.001).Conclusion:Hyperkalemia
Inpatient 40
40 
Cardiometabolic Health Congress (CMHC) will present the results of a webcast series designed to help practitioners improve patient care
Cardiometabolic Health Congress
JUNE 24, 2024
As a leader in the field of research-based cardiometabolic health education, CMHC is proud to present its CME education outcomes study at ADA (American Diabetes Association) 2024 Scientific Sessions, which offers its education-focused agenda to a wide number of healthcare practitioners from all areas of the U.S.
Patient Care 52
52 Abstract 4148106: Hemophilia and Cardiovascular disease in the United States: Prevalence, Risk factors, and outcomes.
Circulation
NOVEMBER 11, 2024
Owing to improved management, the life expectancy of patients with hemophilia has increased significantly and predisposes them to risk of cardiovascular diseases and thrombotic events. The primary outcome was to estimate the prevalence of cardiovascular risk factors in patients with hemophilia compared to the general population.
Risk Factors 40
40 
19th Annual Cardiometabolic Health Congress: Honoring the Life and Legacy of CMHC Co-Chair Dr. George L. Bakris
Cardiometabolic Health Congress
AUGUST 14, 2024
The focus will be on the intricate interplay between cardiorenal and metabolic conditions, such as type 2 diabetes, cardiovascular disease, and chronic kidney disease, driven by lifestyle and health factors. Aronne, MD Expert Perspectives on Initiating and Maintaining Insulin Therapy in Type 2 Diabetes Patients Jay H.
CME 72
72 
Abstract WP294: Racial Disparities among the risk of Stroke and other clinical outcomes post Infective Endocarditis: A Propensity Matched Analysis
Stroke Journal
JANUARY 30, 2025
Propensity score-matched analysis (PSM) (1:1) was performed on age, gender, BMI, hypertension, diabetes mellitus, chronic kidney disease, hemoglobin level, LDL level, left ventricular ejection fraction and various drugs including beta blockers, ACEi and ARBi.
The impact of early cryoballoon ablation on clinical outcome in patients with atrial fibrillation: From the Korean cryoballoon ablation registry
Journal of Cardiovascular Electrophysiology
NOVEMBER 5, 2023
Abstract Introduction Influence of early atrial fibrillation (AF) ablation, particularly cryoballoon ablation (CBA), on clinical outcome during long-term follow-up has not been clarified. The primary outcome was recurrence of atrial tachyarrhythmias (ATs) of ≥30-s after a 3-month blanking period.
Abstract 52: Glucagon-like peptide-1 receptor agonists use and outcomes in Cardiac Amyloidosis patients: A Propensity Matched Analysis
Stroke Journal
JANUARY 30, 2025
Propensity score-matched analysis (PSM) (1:1) was performed with matching for age, gender, race, BMI, hypertension, diabetes mellitus, chronic kidney disease, hemoglobin level, low-density lipid (LDL) level, left ventricular ejection fraction, and various drugs including ACEi, ARBi, ARNI, beta-blockers, and diuretics.
Outcomes 40
40 
Incidence, predictors and clinical implications of new renal impairment following percutaneous coronary intervention
Open Heart
OCTOBER 11, 2022
Within a large cohort of registry patients, we aimed to explore the incidence, predictors and clinical outcomes of renal impairment post-PCI. Methods The Victorian Cardiac Outcomes Registry is an Australian state-based clinical quality registry focusing on collecting data from all PCI capable centres. to 4.39, p<0.001).
Abstract 4141474: Impact of Serum 5-Hydroxytryptophan Levels on Coronary Artery Calcification Severity in Acute Coronary Syndrome Patients: Insights from the Microbiota-Gut-Brain Axis
Circulation
NOVEMBER 11, 2024
The primary exposure variable was 5-HTP levels, and the primary outcome was the severity of coronary calcification assessed through fluoroscopy. to 1.10); diabetes 1.24 (0.67 to 2.31); chronic kidney disease 1.07 (0.33 High 5-HTP levels were significantly associated with more severe calcification (p = 0.04, OR = 3.3,
Mineralocorticoid Receptor Antagonists in Heart Failure: An Update
Circulation: Heart Failure
NOVEMBER 25, 2024
Spironolactone improved outcomes in patients with severely symptomatic HF with reduced ejection fraction, and later, eplerenone expanded the benefits to patients with mildly symptomatic HF with reduced ejection fraction and myocardial infarction complicated by HF. The use of MRAs has been limited due to excessive concern about hyperkalemia.
Multispecialty multidisciplinary input into comorbidities along with treatment optimisation in heart failure reduces hospitalisation and clinic attendance
Open Heart
JULY 20, 2022
Aims Heart failure (HF) is associated with comorbidities which independently influence treatment response and outcomes. Methods Patients acted as their own controls, with outcomes compared for equal periods (for each patient) pre (HF MDT) versus post-MDT (multispecialty) meeting. Results 334 patients (mean age 72.5±11
Top 10 AI Cardiometabolic Startups to Watch in 2025
Cardiometabolic Health Congress
OCTOBER 10, 2024
These companies are at the forefront of innovation, driving improvements in patient outcomes and reshaping the future of healthcare delivery. Vitadio : Digital therapeutics for type 2 diabetes and prediabetes, expanding globally. LumineticsCore : An AI diagnostics company with FDA-cleared systems for detecting diabetic retinopathy.
Innovation 52
52 
Albuminuria in cardiac ATTR amyloidosis: prevalence, progression and prognostic importance
European Journal of Heart Failure
NOVEMBER 23, 2023
Abstract Aims Transthyretin cardiac amyloidosis (ATTR-CA) is an infiltrative cardiomyopathy that commonly presents with concomitant chronic kidney disease. Albuminuria is common in heart failure and associated with worse outcomes, but its prevalence and relationship to outcome in ATTR-CA remains unclear.
Interventions to Attenuate Cardiovascular Calcification Progression: A Systematic Review of Randomized Clinical Trials
Journal of the American Heart Association
NOVEMBER 28, 2023
BackgroundCardiovascular calcification, characterized by deposition of calcium phosphate in the arterial wall and heart valves, is associated with cardiovascular morbidity and mortality and is commonly seen in aging, diabetes, and chronic kidney disease.
Cardiometabolic Health Congress Becomes First Organization to Offer Certification in Cardiometabolic Health
Cardiometabolic Health Congress
NOVEMBER 8, 2023
2023, the American Heart Association (AHA) issued a presidential advisory on the urgency of this systemic disorder involving heart disease, kidney disease, diabetes and obesity. The virtual, self-paced Foundations of Cardiometabolic Health Certificate Course is the first step to attaining the CCHP credential.
Abstract 4147960: Intensive treatment compared to Standard for hypertension in elderly patients, is it safe and effective? A Systematic Review and Meta-Analysis
Circulation
NOVEMBER 11, 2024
Evaluate the benefit in important cardiovascular outcomes and safety in elderly patients of a blood pressure control ≤ 130mmHg compared to standard of care.Methods:The research was performed in PubMed, EMBASE, Scielo, LILACS, and Cochrane Central Register of Controlled Trials (CENTRAL) from January 1st, 2013 to May 1st, 2023.
Abstract 49: Genomic Profiling and Risk of Intracerebral Hemorrhage in Patients with Atrial Fibrillation on Apixaban
Stroke Journal
JANUARY 30, 2025
Hypertension, diabetes, hyperlipidemia, and chronic kidney disease are well-known cardiovascular risk factors for ICH. Stroke, Volume 56, Issue Suppl_1 , Page A49-A49, February 1, 2025. Introduction:Intracranial hemorrhage (ICH) is the most severe adverse effect of anticoagulation in atrial fibrillation (AF) patients.
Abstract 52: Predictors of Mortality in Patients With Various Rheumatological Conditions Admitted for Stroke: Findings From National Inpatient Sample 2020
Stroke Journal
FEBRUARY 1, 2024
We compared demographics, hospital traits, comorbidities, and outcomes. In-hospital mortality, our primary outcome, was analyzed through multivariate logistic regression using STATA 18.Results:Incorporating to 2.26) and liver disease (OR 2.20, p < 0.01, CI 1.27
Inpatient 40
40 
Top 10 Cardiac Diagnosis Trends in 2024
GEMMS
MAY 22, 2024
This improves diagnostic accuracy and ultimately leads to better patient outcomes. Artificial Intelligence Artificial intelligence (AI) has revolutionized cardiac diagnosis by allowing for the analysis of extensive patient data to identify patterns and predict outcomes.
Early Rhythm Control, Lifestyle Modification and More Tailored Stroke Risk Assessment Are Top Goals in Managing Atrial Fibrillation
DAIC
DECEMBER 8, 2023
For example, kidney disease is not included in CHA 2 DS 2 -VASc. Similar to other chronic conditions, such as high blood pressure or Type 2 diabetes, Joglar said we “now have a better understanding and more tools to prevent, treat and also mitigate the risk of AFib so that we can improve patient outcomes.”
Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research in Chronic Kidney Disease at ACC.25
DAIC
MARCH 25, 2025
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25
FDA Accepts, Grants Priority Review Designation for Bayer's msNRA for Patients with Heart Failure
DAIC
MARCH 26, 2025
2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). 2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). 4 Approximately 6.7 million adults in the U.S. 4 Approximately 6.7
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: A FIDELITY analysis
European Journal of Heart Failure
JANUARY 17, 2025
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: a FIDELITY analysis. c CV composite outcome component(s). d Composite of time to kidney failure, sustained 57% decrease in eGFR from baseline over 4weeks, or kidney-related death. vs. 8.3%).
Risk factors, outcomes and healthcare utilisation in individuals with multimorbidity including heart failure, chronic kidney disease and type 2 diabetes mellitus: a national electronic health record study
Open Heart
SEPTEMBER 27, 2023
Background Heart failure (HF), type 2 diabetes (T2D) and chronic kidney disease (CKD) commonly coexist. We studied characteristics, prognosis and healthcare utilisation of individuals with two of these conditions.
Risk Factors 52
52 
Creative Alliances in Cardiorenal Metabolic Management: A Game Changer (Part 1)
Cardiometabolic Health Congress
AUGUST 8, 2024
Cardiometabolic risk encompasses a complex spectrum of interrelated conditions, including cardiovascular disease, type 2 diabetes, and metabolic syndrome. This blog post explores the development of such partnerships and their potential to transform healthcare outcomes.
Education 59
59 
Semaglutide Shows Benefit in CKD and Type 2 Diabetes Across Kidney Disease Severities
HCPLive
OCTOBER 26, 2024
in the composite primary outcome of kidney failure, serious eGFR decline, or death compared to placebo. Participants receiving semaglutide had an overall hazard ratio of 0.76
EMPACT-MI Trial Outcomes Reported at ACC24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack
DAIC
APRIL 6, 2024
SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. Researchers tracked outcomes for a median of just under 18 months. All secondary endpoints related specifically to heart failure outcomes were significantly reduced among patients who received empagliflozin.
Heart Attack 81
81 
National A-Fib Numbers Higher Than Previously Thought
DAIC
SEPTEMBER 11, 2024
A-Fib, as the condition is commonly known, has been on the rise for at least the past decade, driven by the aging of the population, along with increasing rates of hypertension, diabetes and obesity. Earlier projections had estimated that 3.3 million U.S. The study appears Sept. 11 in the Journal of the American College of Cardiology JACC.
Abstract DP47: The Role of Chronic Kidney Disease and Brain Iron Deposition in Intracerebral Hemorrhage
Stroke Journal
JANUARY 30, 2025
Introduction:Chronic kidney disease (CKD) is a risk factor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH. For each patient, eGFR along with age, sex, race, ethnicity, hypertension, diabetes (DM), heart disease, and hyperlipidemia were abstracted.
Let's personalize your content